Cancers (Mar 2021)

Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy

  • Kae Nakamura,
  • Nobuhisa Yoshikawa,
  • Yuko Mizuno,
  • Miwa Ito,
  • Hiromasa Tanaka,
  • Masaaki Mizuno,
  • Shinya Toyokuni,
  • Masaru Hori,
  • Fumitaka Kikkawa,
  • Hiroaki Kajiyama

DOI
https://doi.org/10.3390/cancers13051141
Journal volume & issue
Vol. 13, no. 5
p. 1141

Abstract

Read online

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The major cause of EOC’s lethality is that intraperitoneal recurrence occurs with high frequency due to occult metastasis. We had demonstrated that plasma-activated medium (PAM) exerts a metastasis-inhibitory effect on ovarian cancer in vitro and in vivo. Here we investigated how PAM inhibits intraperitoneal metastasis. We studied PAM’s inhibition of micro-dissemination onto the omentum by performing in vivo imaging in combination with a sequential histological analysis. The results revealed that PAM induced macrophage infiltration into the disseminated lesion. The iNOS-positive signal was co-localized at the macrophages in the existing lesion, indicating that PAM might induce M1-type macrophages. This may be another mechanism of the antitumor effect through a PAM-evoked immune response. Intraperitoneal lavage with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Our results demonstrated the efficiency and practicality of aqueous plasma for clinical applications.

Keywords